TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. ("Dialco"), today announced the results of its Annual and Special Meeting of shareholders (the "Shareholders") held on June 20, 2022 (the "Meeting"). The Company is pleased to announce that all resolutions put forward in the Management Information Circular dated May 6, 2022 (the "Circular") to its Shareholders were approved.
Results of the matters voted on at the Meeting are set out below.
Election of Directors
Spectral's eight director nominees were elected:
| Nominee | Votes For (percent) | Votes Withheld (percent) |
| Jan D'Alvise | 99.07% | 0.93% |
| Anthony Bihl III | 97.30% | 2.70% |
| Jun Hayakawa | 99.14% | 0.86% |
| John Nosenzo | 97.17% | 2.83% |
| Chris Seto | 71.28% | 28.72% |
| William Stevens | 94.95% | 5.05% |
| Paul Walker | 97.16% | 2.84% |
| James Funk | 99.17% | 0.83% |
Appointment of Auditors
PricewaterhouseCoopers LLP, Chartered Accountants, was re-appointed as auditor of Spectral.
Votes For: 99.67%
Votes Withheld: 0.33%
Approval of Consolidation
A special resolution authorizing the future amendment of the articles of the Company to consolidate all of the Company's issued and outstanding common shares (the "Shares"), on the basis of a consolidation ratio in the range of 1 post-consolidation Share for 10 pre-consolidation Shares to 1 post-consolidation Share for 20 pre-consolidation Shares to be selected by the board of directors of the Corporation (the "Board"), at such time as the Board so determines within 12 months of the date of the Meeting was approved.
Votes For: 72.93%
Votes Withheld: 27.07%
About Spectral Medical Inc.
Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ("PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.
PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 340,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.
Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market. Dialco is currently pursuing regulatory approval for U.S. in-home use of DIMI, which is based on the same RRT platform as SAMI, but will be intended for home hemodialysis use. DIMI recently received its FDA 510k clearance for use in hospital and clinical settings, and obtained its Health Canada license for use within Canadian hospitals, clinics and in home.
Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.
Forward-looking statements
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
For further information, please contact:
| Mr. Blair McInnis CFO Spectral Medical Inc. 416-626-3233 bmcinnis@spectraldx.com | Ali Mahdavi Capital Markets & Investor Relations 416-962-3300 am@spinnakercmi.com | David Waldman/Natalya Rudman US Investor Relations Crescendo Communications, LLC 212-671-1020 edt@crescendo-ir.com |
